<DOC>
	<DOCNO>NCT01200212</DOCNO>
	<brief_summary>The purpose study determine whether - Paclitaxel bevacizumab show improved PFS compare paclitaxel alone . Recent result AVADO study report similar result combination docetaxel bevacizumab . The AVADO study furthermore confirm dose 15 mg/kg BW bevacizumab . - As metastatic breast cancer ( MBC ) poly-chemotherapies frequently use , regimens bevacizumab least 2 cytotoxic agent investigate . - Docetaxel capecitabine show benefit PFS survival . This combi- nation therefore reasonable choice . - Dose capecitabine docetaxel reduce 1800 mg/m2 75 mg/m2 improve tolerability without compromise efficacy . - Paclitaxel capecitabine well tolerate show PFS 10.3 month . - Docetaxel 100 mg/m2 monotherapy MBC often use b/o toxicity . 75 mg/m2 much accept daily practice . Better comparability DBX , arm 75mg/m2 docetaxel assume .</brief_summary>
	<brief_title>A Randomized Study Determine Efficacy Taxane Bevacizumab With Without Capecitabine First Line Chemotherapy Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Primary Objective : - To determine Progression Free Survival ( PFS ) patient metastatic breast cancer treatment taxane plus bevacizumab ( TXB ) without capecitabine ( TB ) . Secondary Objective ( ) : - To determine objective response rate arm . - To determine duration response arm . - To determine Time Progression ( TTP ) arm . - To determine clinical benefit define CR , PR , stable disease ≥ 24 week arm . - To determine overall survival rate 3 year `` Last Patient In '' . - To determine PFS TTP response rate patient 's ≥ age 65 . - To determine toxicity compliance arm . - To determine predictive value serum marker VEGF .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>ECOG performance status 02 Histological confirm carcinoma breast expression HER2 Locally advance metastatic stage disease suitable surgery radiotherapy alone Patients must either measurable nonmeasurable target lesion accord RECIST criterion ( phase III ) . Complete stag workup within 4 week prior registration . All patient must chest Xray ( PA lateral ) , abdominal ultrasound CT scan MRI , bone scan . In case positive bone scan , bone Xray mandatory . Other test may per form clinically indicate The follow previous systemic treatment eligible : ( neo ) adjuvant chemotherapy ( except capecitabine include ) However ( neo ) adjuvant chemotherapy anthracycline base , maximum cumulative dose prior anthracycline therapy must exceed 360 mg/m2 doxorubicin 720 mg/m2 epirubicin . If taxanes capecitabine part ( neo ) adjuvant treatment , treatmentfree interval &gt; 6 month request adjuvant endocrine therapy . palliative endocrine treatment treatment bisphosphonates treatment immunotherapy Patient fully recover previous radiotherapy . At least one measurable lesion must completely outside radiation field must pathologic proof progressive disease Absolute neutrophil count ≥ 2000 cells/ul , platelet count ≥ 100,000 cells/ul . Bilirubin ≤ 1.5x upper limit normal institution ( ULN ) ; elevation transaminases alkaline phosphatase &lt; 2.5x ULN &lt; 5x ULN patient liver metastasis Creatinine ≤ 1,25x ULN creatininclearance &gt; 50 ml/min ( accord Cockroft Gault ) . Urine dipstick proteinuria &lt; 2+ . Patients discover ≥2+ proteinuria dipstick urinalysis undergo 24 hour urine collection must demonstrate ≤1 g protein 24 hour Negative pregnancy test ( urine serum ) within 14 day prior registration woman childbearing potential Patients must available compliant treatment followup . Patients register trial must treat follow participate cooperate site Known hypersensitivity reaction compound incorporated substance know dihydropyrimidine dehydrogenase deficiency Previous chemotherapy metastatic disease , concurrent immunotherapy hormonal therapy ( antihormonal , contraceptive and/or replacement therapy ) . Bisphosphonates may continue Life expectancy le 3 month Serious intercurrent medical psychiatric illness may interfere plan treatment ( include AIDS serious active infection ) . Known suspected congestive heart failure ( &gt; NYHA I ) and/or coronary heart disease , angina pectoris require antianginal medication , previous history myocardial infarction , evidence transmural infarction ECG , un poorly control arterial hypertension ( i.e . BP &gt; 150/100 mmHg treatment two antihypertensive drug ) , rhythm abnormality require permanent treatment , clinically significant valvular heart disease Currently active infection Active peptic ulcer , incomplete wound heal unhealed bone fracture Previous thromboembolic event , know hemorrhagic diathesis , coagulopathy increase bleeding risk , treatment anticoagulant Current recent ( within 10 day first dose bevacizumab ) use acetylic acid ( &gt; 325mg/day ) clopidogrel ( &gt; 75mg/day ) Disease significantly affect gastrointestinal function , e.g . mal absorption syndrome , resection stomach small bowel , ulcerative colitis ; abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month enrolment Major surgery within last 28 day anticipation need major surgery study treatment bevacizumab . No minor surgery include insertion indwelling catheter within 24 h prior randomization Parenchymal brain metastasis , unless adequately control surgery and/or radiotherapy complete resolution symptom discontinuation steroid History malignancy within last 5 year could affect diagnosis assessment outcome metastatic breast cancer Concurrent treatment experimental drug ; participation another clinical trial investigational drug within 30 day prior study entry Treatment sorivudine derivates e.g . brivudine Pregnant lactating patient . Patients childbearing potential must implement adequate nonhormonal contraceptive measure ( barrier method , intra uterine contraceptive device , sterilization ) study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Palliative Therapy</keyword>
	<keyword>bevacizimab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Xeloda</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>Progression Free Survival</keyword>
	<keyword>Time Progression</keyword>
	<keyword>Overall survival</keyword>
</DOC>